Synovus Financial Corp Acquires 1,539 Shares of Novo Nordisk A/S (NVO)

Synovus Financial Corp lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 23.3% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 8,154 shares of the company’s stock after buying an additional 1,539 shares during the quarter. Synovus Financial Corp’s holdings in Novo Nordisk A/S were worth $385,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. Chicago Partners Investment Group LLC lifted its position in shares of Novo Nordisk A/S by 762.5% in the 2nd quarter. Chicago Partners Investment Group LLC now owns 3,131 shares of the company’s stock worth $144,000 after buying an additional 2,768 shares during the last quarter. Schroder Investment Management Group bought a new position in shares of Novo Nordisk A/S in the 2nd quarter worth about $182,000. Legacy Financial Advisors Inc. lifted its position in shares of Novo Nordisk A/S by 527.8% in the 3rd quarter. Legacy Financial Advisors Inc. now owns 3,886 shares of the company’s stock worth $183,000 after buying an additional 3,267 shares during the last quarter. Stevens Capital Management LP bought a new position in shares of Novo Nordisk A/S in the 2nd quarter worth about $202,000. Finally, 180 Wealth Advisors LLC bought a new position in shares of Novo Nordisk A/S in the 2nd quarter worth about $215,000. Institutional investors own 6.72% of the company’s stock.

A number of research firms have recently issued reports on NVO. Cfra restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Friday, November 2nd. ValuEngine upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Saturday, October 27th. HSBC reiterated a “sell” rating on shares of Novo Nordisk A/S in a research report on Tuesday. Kepler Capital Markets reiterated a “hold” rating on shares of Novo Nordisk A/S in a research report on Thursday, October 18th. Finally, Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, July 31st. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company’s stock. Novo Nordisk A/S has an average rating of “Hold” and a consensus target price of $64.00.

Shares of NYSE:NVO opened at $44.67 on Friday. The stock has a market capitalization of $105.44 billion, a P/E ratio of 19.09, a PEG ratio of 2.28 and a beta of 0.76. Novo Nordisk A/S has a fifty-two week low of $41.23 and a fifty-two week high of $58.37.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, August 8th. The company reported $0.68 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.64 by $0.04. The firm had revenue of $4.39 billion for the quarter, compared to the consensus estimate of $4.33 billion. Novo Nordisk A/S had a net margin of 34.94% and a return on equity of 81.50%. On average, equities analysts predict that Novo Nordisk A/S will post 2.44 earnings per share for the current year.

WARNING: This report was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://sportsperspectives.com/2018/11/09/synovus-financial-corp-acquires-1539-shares-of-novo-nordisk-a-s-nvo.html.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.

Recommended Story: What are the economic characteristics of a bear market?

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply